QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy

Solid Tumor Clinical Trial

— QUANTACT  

Official title:

QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04762862
• Other study ID #: 21LGTS01
• Status: Enrolling by invitation
• Start date: February 1, 2021
• Est. completion date: December 31, 2021

Study information

• Verified date: February 2021
• Source: Centre Hospitalier Universitaire de Nice
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

"Precision medicine and targeted therapies have played a crucial role over the past ten years in the personalized care of cancer patients. In this retrospective and observational study, we focused on patients for which no standard or curative treatment was available and for which the management was discussed in a Molecular Tumor Board (MTB).

The role of the MTB is to decide the most appropriate therapeutic options for patients according to the potential identification of molecular targets.

Among the analyses carried out, we focused on a quantitative genome-wide analysis: the CGH/SNP-array (Comparative Genomic Hybridization / Single Nucleotide Polymorphism on array). The objective was to evaluate the impact of CGH/SNP-array analyses in the identification of targeted molecular alterations.

"

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 1200
• Est. completion date: December 31, 2021
• Est. primary completion date: August 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed solid tumor malignancy that is advanced or metastatic ;

• no standard or curative treatment available;

• non-opposition of the patient collected.

Exclusion Criteria:

• multiple cancer patient;

• ECOG Scale of Performance Status (PS) =2

Related Conditions & MeSH terms

• Solid Tumor

Locations

Country	Name	City	State
France	CHU de Nice	Nice

Sponsors (2)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice	Centre Antoine Lacassagne

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of targeted molecular alterations	Number of targeted molecular alterations	at day 0
Secondary	Number of patients eligible for targeted therapy (clinical trials or "off-label" drug)	Number of patients eligible for targeted therapy (clinical trials or "off-label" drug)	at day 0